Medtronic has presented two years of follow-up study results of its Resolute drug-eluting stent (DES).
The study, which enrolled 878 standard risk2 diabetes patients and 1,903 patients without diabetes, will compare the clinical outcomes associated with the Resolute DES in risk2 diabetes patients to patients without diabetes.
The analysis will show low event rates out to two years for both groups, despite the higher-risk nature of the diabetes patient population.
At two years of follow-up, rates of target lesion failure (TLF) are 7.1% for the patients without diabetes and 9.6% for patients with diabetes.
The analysis will also feature additional outcomes for safety measures, comparing insulin-dependent- and non-insulin-dependent diabetes patients to patients without diabetes.
Rates are similar among non-insulin-dependent diabetes patients and patients without diabetes.
